2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 696

The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
Abstract Number: 2427

The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort
Abstract Number: 1052

The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension
Abstract Number: PP10

The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis
Abstract Number: 1938

The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Abstract Number: 2769

The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis
Abstract Number: 2762

The Preparation and Recovery Experience from Total Knee Replacement of Patients with Osteoarthritis: A Qualitative Study
Abstract Number: 962

The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Abstract Number: 893

The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome
Abstract Number: 1263

The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center
Abstract Number: 2071

The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project)
Abstract Number: 667

The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Abstract Number: 1761

The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Abstract Number: 1974

The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection
Abstract Number: 1879

The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].